Matthew Wiley

Insider Reports History

Entity
Individual
Location
C/O Foamix Pharmaceuticals Ltd., 2 Holtzman St, Weizmann Science Park, Rehovot, Israel
Signature
/s/ Richard Steinhart, Attorney-in-Fact for Matthew Wiley
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Matthew Wiley:

Stock Role Class Num Shares Value Price $ Report Date Ownership
VYNE Therapeutics Inc. Chief Commercial Officer Common Stock 109K $249K $2.28 Jun 30, 2021 Direct
BioXcel Therapeutics, Inc. Chief Commercial Officer Common Stock 19K $10.5K $0.55 Oct 3, 2024 Direct
BioXcel Therapeutics, Inc. Chief Commercial Officer Restricted Stock Units 7.5K $9.6K $1.28 Sep 15, 2024 Direct

Insider Reports Filed by Matthew Wiley

Symbol Company Period Transactions Value $ Form Type Date Filed Role
BTAI BioXcel Therapeutics, Inc. Sep 17, 2024 2 -$3.45K 4 Oct 3, 2024 Chief Commercial Officer
BTAI BioXcel Therapeutics, Inc. Sep 15, 2024 3 -$149 4 Sep 17, 2024 Chief Commercial Officer
BTAI BioXcel Therapeutics, Inc. Jun 15, 2024 1 $0 4/A Sep 17, 2024 Chief Commercial Officer
BTAI BioXcel Therapeutics, Inc. Mar 15, 2024 3 -$2.66K 4 Apr 8, 2024 CHIEF COMMERCIAL OFFICER
BTAI BioXcel Therapeutics, Inc. Mar 15, 2023 2 $0 4 Mar 16, 2023 CHIEF COMMERCIAL OFFICER
BTAI BioXcel Therapeutics, Inc. Jan 17, 2022 1 $0 4 Jan 19, 2022 CHIEF COMMERCIAL OFFICER
BTAI BioXcel Therapeutics, Inc. Jan 17, 2022 0 $0 3 Jan 19, 2022 CHIEF COMMERCIAL OFFICER
VYNE VYNE Therapeutics Inc. Jun 30, 2021 1 -$18.1K 4 Jul 2, 2021 Chief Commercial Officer